Los Angeles Capital Management
TNXP icon

Los Angeles Capital Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Los Angeles Capital Management’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.04K Sell
76
-9,192
-99% -$141K ﹤0.01% 2342
2025
Q4 		$167K Buy
+9,268
New +$171K ﹤0.01% 1288

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Los Angeles Capital Management's TNXP Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Tonix Pharmaceuticals (TNXP) stake by 99% in Q1 2026, selling an estimated $141K and leaving 76 shares worth $1.04K. The position accounts for ﹤0.01% of the portfolio, ranked #2342.

Los Angeles Capital Management first reported a position in TNXP in Q4 2025 and has held it in 2 quarters since. The position peaked at $167K in Q4 2025. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • Los Angeles Capital Management held 76 shares of Tonix Pharmaceuticals worth $1.04K as of Q1 2026.
  • Los Angeles Capital Management sold 9,192 Tonix Pharmaceuticals shares in Q1 2026, an estimated $141K.
  • Tonix Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2342 holding.
  • Los Angeles Capital Management first reported a position in Tonix Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Los Angeles Capital Management's Tonix Pharmaceuticals position peaked at $167K in Q4 2025.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.